GlobeNewswire by notified

Metalpha Technology Holding Limited to Expand its Presence in Digital Asset Wealth Management

Share

Metalpha is focused on serving institutional investors and high-net-worth individuals, while also emphasizing its commitment to transparency and regulatory compliance

HONG KONG, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Dragon Victory International Limited (NASDAQ: LYL) announces it has officially changed its name to Metalpha Technology Holding Limited (NASDAQ: MATH) (the “Company”). The Company has also successfully completed restructuring with Antalpha Technologies Limited (“Antalpha”).

Upon completion of the reorganization, Metalpha Limited (“Metalpha”) will become a wholly-owned subsidiary of the Company. Established in 2021, Metalpha is a leading digital assets wealth management company headquartered in Hong Kong. The company works with clients to create tailor-made instruments that enable sophisticated investors to establish or liquidate investment positions or undertake hedging strategies.

This reorganization demonstrates a high level of confidence that the Company’s management team has in Metalpha's ability to increase its presence and develop a competitive advantage under the current market conditions. The reorganization is intended to pave the way for new opportunities for Metalpha to become a global leader in digital asset wealth management. Metalpha employs finance talents with deep experience in derivatives and structured products, many of whom formerly worked at industry-leading banks such as Goldman Sachs, Morgan Stanley, and UBS.

“The crypto industry continues to have room for growth, despite its challenges this year. We are looking very closely at how to build a stronger and healthier global market for digital assets, which we are doing together with our partners, such as Antalpha, and many others,” said Founder and CEO Adrian Wang.

Metalpha aims to provide customers with high-quality product design and trading capabilities in the industry and is committed to delivering the best structured derivative products to cryptocurrency market participants. The company does not offer services to Mainland China and pursues the highest level of compliance standards in every jurisdiction it operates in.

Looking ahead, the Company will actively work with regulators on various compliance measures and plans to invest in supporting public education in blockchain technology and hiring more personnel at its headquarters in Hong Kong.

About Metalpha Limited

Established in 2021, Metalpha Limited is a global digital assets wealth management company headquartered in Hong Kong. The company hires top talents from Wall Street banks and provides crypto derivative products to institutions, which include exchanges, miners, funds, family offices, etc. Backed by both Metalpha Technology Holding Limited (NASDAQ: MATH) and Antalpha Technologies Limited, the company is one of the largest derivatives traders in Asia.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties, including the further spread of the COVID-19 virus or new variants thereof, or the occurrence of another wave of cases and the impact it may have on the Company's operations and the demand for the Company's services, and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to," or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and its other filings with the U.S. Securities and Exchange Commission.

Contact

Sissy Wang
info@metalpha.finance

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f833b6db-cfdf-45f7-8153-47657357042f

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia9.5.2024 17:06:04 CEST | Press release

RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) -- Harvard University -- Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care. Strategic investments in infrastructure, technology, and talent, have led to advancements revolutionizing patient care delivery and elevating the standards of healthcare locally. These efforts have notably raised the average life expectancy, reduced mortality rates, and enhanced overall well-being across the Kingdom. Central to these achievements, King Faisal Specialist Hospital & Research Centre (KFSH&RC), renowned for its specialized care and treatments across critical fields such as oncology, cardiology, organ transplantation, and genetics has positioned itself as a leader in specialized patient care, taking the charge towards a brighter, healthier future for the Kingdom. Through its commitment to pioneering digital health initiatives, comprehensive educational programs, and

Corza Medical Named “Best Overall MedTech Company” in 8th Annual MedTech Breakthrough Awards Program9.5.2024 16:30:00 CEST | Press release

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies WESTWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corza Medical today announced that it has been selected as the winner of the “Best Overall MedTech Company” award in the 8th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market. Corza Medical provides healthcare professionals with a platform of surgical technologies and features industry-leading brands. The company partners closely with clinicians and surgical providers to create a differentiated surgical experience through remarkable products and services that save time, money, and effort. Working with diverse healthcare providers ranging from hospital administrators to private practices, this exceptional medical device

Skyborne Technologies Unveils the Cerberus Modular Integration9.5.2024 16:10:00 CEST | Press release

BRISBANE, Australia, May 10, 2024 (GLOBE NEWSWIRE) -- Skyborne Technologies is proud to unveil Cerberus Modular Integration (MI), a multi-mission, man-packable, Group 2 sUAS equipped with modular kinetic and non-kinetic payloads. The Cerberus MI builds upon years of research, development and aerial fire testing, and is one of the first Group 2 lethal sUAS on the market. The system is capable of delivering organic strike capabilities at the tactical level with a re-usable and re-loadable kinetic payloads. The requirements for the Cerberus MI have been driven by Skyborne’s contracting customers, the Australian Defence Force, UK Ministry of Defence and US Department of Defence. The latest Cerberus includes the following key enhancements: Modular kinetic and non-kinetic payloads - offering multi-mission sUAS capability. Current payloads: UxV weapon HAVOC® 40mm Grenade Launcher – 5-shot 40mmUxV weapon CHAOS® 12GA Shotgun – 10-shot 12GAElectronic Warfare (SIGINT / EA)CBRNE (Radiological) Sen

Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results9.5.2024 16:00:00 CEST | Press release

Press Release – No. 4 / 2024 Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results Copenhagen, Denmark, May 9, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 16, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter of 2024. Presenting during the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session. The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at https://edge.media-server.com/mmc/p/ee4aippx. To receive telephone dial-in information and a unique personal access PIN, please register at https://register.vevent.com/register/BI

Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest9.5.2024 15:00:00 CEST | Press release

ALBANY, N.Y. and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization and Carterra Inc., the world leader in label-free high throughput antibody and small molecule drug discovery, today announced their partnership in hosting a high-throughput biologics symposium slated for May 31 at the Residence Inn at Marriott in Seattle, Washington. The purpose of the collaboration is to promote the rising biotech focus within the Pacific Northwest region of the U.S and Canada. The symposium will bring together all levels of scientific leadership from the biotech and pharma communities. "We are thrilled to be partnering with Carterra to organize this antibody discovery symposium, bringing the Pacific Northwest biotech community together and sharing the latest advances in antibody discovery," said Steve Lavezoli, Vice President of Biologics at Curia. "We are also looking forward to sharing our optimal, high-quality and acceler

HiddenA line styled icon from Orion Icon Library.Eye